{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:55:31Z","timestamp":1790470531332,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Bacteria belonging to the genus Achromobacter are increasingly isolated from respiratory samples of people with cystic fibrosis (PWCF). The management of this multidrug-resistant genus is challenging and characterised by a lack of international recommendations, therapeutic guidelines and data concerning antibiotic susceptibility, especially concerning the newer antibiotics. The objective of this study was to describe the antibiotic susceptibility of Achromobacter isolates from PWCF, including susceptibility to new antibiotics. The minimum inhibitory concentrations (MICs) of 22 antibiotics were determined for a panel of 23 Achromobacter isolates from 19 respiratory samples of PWCF. Two microdilution MIC plates were used: EUMDROXF\u00ae plate (Sensititre) and Micronaut-S Pseudomonas MIC\u00ae plate (Merlin) and completed by a third method if necessary (E-test\u00ae or UMIC\u00ae). Among usual antimicrobial agents, the most active was imipenem (70% susceptibility). Trimethoprim-sulfamethoxazole, piperacillin and tigecycline (65%, 56% and 52% susceptibility, respectively) were still useful for the treatment of Achromobacter infections. Among new therapeutic options, \u03b2-lactams combined with a \u03b2-lactamase-inhibitor did not bring benefits compared to \u03b2-lactam alone. On the other hand, cefiderocol appeared as a promising therapeutic alternative for managing Achromobacter infections in PWCF. This study provides the first results on the susceptibility of clinical Achromobacter isolates concerning new antibiotics. More microbiological and clinical data are required to establish the optimal treatment of Achromobacter infections.<\/jats:p>","DOI":"10.3390\/microorganisms9122473","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T05:42:10Z","timestamp":1638250930000},"page":"2473","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-2947","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Beauruelle","sequence":"first","affiliation":[{"name":"University Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, France"},{"name":"Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Lamoureux","sequence":"additional","affiliation":[{"name":"University Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, France"},{"name":"Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsid","family":"Mashi","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ramel","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Fondation Ildys, Presqu\u2019\u00eele de Perharidy, 29680 Roscoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Le Bihan","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Fondation Ildys, Presqu\u2019\u00eele de Perharidy, 29680 Roscoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ropars","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Fondation Ildys, Presqu\u2019\u00eele de Perharidy, 29680 Roscoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dirou","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Fondation Ildys, Presqu\u2019\u00eele de Perharidy, 29680 Roscoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandadev","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Fondation Ildys, Presqu\u2019\u00eele de Perharidy, 29680 Roscoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Tand\u00e9","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Le Bars","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-3825","authenticated-orcid":false,"given":"Genevi\u00e8ve","family":"H\u00e9ry-Arnaud","sequence":"additional","affiliation":[{"name":"University Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, France"},{"name":"Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref_1","unstructured":"(2021, September 07). Registre Fran\u00e7ais de la Mucoviscidose Bilan Des Donn\u00e9es. Available online: https:\/\/www.vaincrelamuco.org\/sites\/default\/files\/registre_2019_vf.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"00076","DOI":"10.1183\/23120541.00076-2021","article-title":"Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis","volume":"7","author":"Marsac","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcf.2006.05.011","article-title":"Achromobacter xylosoxidans in Cystic Fibrosis: Prevalence and clinical relevance","volume":"6","author":"Schelstraete","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1099\/jmm.0.000763","article-title":"Effect of Respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis","volume":"67","author":"Recio","year":"2018","journal-title":"J. Med. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"00051","DOI":"10.1183\/23120541.00051-2019","article-title":"Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis","volume":"5","author":"Tetart","year":"2019","journal-title":"ERJ Open Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1513\/AnnalsATS.201701-071OC","article-title":"Clinical outcomes associated with Achromobacter species infection in patients with cystic fibrosis","volume":"14","author":"Somayaji","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/CMR.00036-10","article-title":"Clinical significance of microbial infection and adaptation in cystic fibrosis","volume":"24","author":"Hauser","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Menetrey, Q., Sorlin, P., Jumas-Bilak, E., Chiron, R., Dupont, C., and Marchandin, H. (2021). Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging pathogens well-armed for life in the cystic fibrosis patients\u2019 lung. Genes, 12.","DOI":"10.3390\/genes12050610"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e01025-20","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter infections and treatment options","volume":"64","author":"Isler","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","unstructured":"(2021, September 07). EUCAST: Consultations. Available online: https:\/\/www.eucast.org\/publications_and_documents\/consultations\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1017\/S0950268816002624","article-title":"Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis","volume":"145","author":"Pereira","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_12","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie (2018). R\u00e9mic\u2014R\u00e9f\u00e9rentiel en Microbiologie M\u00e9dicale, Soci\u00e9t\u00e9 Franc\u0327aise de Microbiologie. [6th ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcf.2012.10.002","article-title":"Identification and distribution of Achromobacter species in cystic fibrosis","volume":"12","author":"Spilker","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_14","unstructured":"(2018, October 29). EUCAST: Clinical Breakpoints. Available online: http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"ref_15","unstructured":"(2021, September 07). EUCAST: Disk Diffusion Methodology. Available online: https:\/\/www.eucast.org\/ast_of_bacteria\/disk_diffusion_methodology\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dkq037","article-title":"Editorial: Assessing the antimicrobial susceptibility of bacteria obtained from animals","volume":"65","author":"Schwarz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","unstructured":"CLSI (2021, September 08). Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition. Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A Coefficient of Agreement for Nominal Scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ. Psychol. Meas."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The Measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1128\/AAC.32.2.276","article-title":"In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents","volume":"32","author":"Glupczynski","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jcf.2019.04.005","article-title":"Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137","volume":"18","author":"Amoureux","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcf.2019.11.005","article-title":"The UK CF Surveillance Working Group comprised. Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis","volume":"19","author":"Coward","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e01595-19","DOI":"10.1128\/AAC.01595-19","article-title":"In vitro activities of \u03b2-Lactam-\u03b2-Lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens","volume":"64","author":"Caverly","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.39.11.3942-3945.2001","article-title":"Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis","volume":"39","author":"Saiman","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jcf.2012.08.005","article-title":"Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French Data","volume":"12","author":"Amoureux","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00951-20","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol antimicrobial susceptibility testing considerations: The Achilles\u2019 heel of the trojan horse?","volume":"59","author":"Simner","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e01955-19","DOI":"10.1128\/AAC.01955-19","article-title":"Activity of cefiderocol and comparators against isolates from cancer patients","volume":"64","author":"Rolston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","unstructured":"Clinical and Laboratory Standards Institute (2017). June, 2017 AST Agenda Summary Minutes, Clinical and Laboratory Standards Institute."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections","volume":"73","author":"Warner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","unstructured":"Food and Drug Administration FDA Antimicrobial Drugs Advisory Committee (2021, November 29). Cefiderocol Briefing Document, Available online: https:\/\/www.fda.gov\/media\/131705\/download."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_33","unstructured":"Caillon, J., Lemabecque, V., Carrere, J., Pelletier, M., Batard, E., and Jacqueline, C. (2009, January 12\u201315). In vitro activity of meropenem (MEM), colistin (CS) and tigecycline (TGC) against Achromobacter xylosoxidans (AX) isolated from cystic fibrosis (CF) patients. Proceedings of the Forty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e01264-21","DOI":"10.1128\/AAC.01264-21","article-title":"Minocycline activity against unusual clinically significant Gram-negative pathogens","volume":"65","author":"Shortridge","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jac\/dkaa066","article-title":"In vitro activity of 20 antibiotics against Cupriavidus clinical strains","volume":"75","author":"Massip","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/dky423","article-title":"In vitro activity of seven \u03b2-lactams including ceftolozane\/tazobactam and ceftazidime\/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients","volume":"74","author":"Massip","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","first-page":"100757","article-title":"Investigation of Stenotrophomonas Maltophilia Epidemiology in a French Cystic Fibrosis Center","volume":"78","author":"Capaldo","year":"2020","journal-title":"Respir. Med. Res."},{"key":"ref_38","first-page":"1","article-title":"Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory tract samples: A 10-year epidemiological snapshot","volume":"6","year":"2019","journal-title":"Health Serv. Res. Manag. Epidemiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"dlab081","DOI":"10.1093\/jacamr\/dlab081","article-title":"In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 Studies in France","volume":"3","author":"Naas","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gavioli, E.M., Guardado, N., Haniff, F., Deiab, N., and Vider, E. (2021). Does cefiderocol have a potential role in cystic fibrosis pulmonary exacerbation management?. Microb. Drug Resist., Online ahead of print.","DOI":"10.1089\/mdr.2020.0602"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgar.2021.07.014","article-title":"In vitro activity of cefiderocol and comparators against gram-negative bacterial isolates from a series of surveillance studies in England: 2014\u20132018","volume":"27","author":"Gant","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_42","unstructured":"(2021, September 10). EUCAST: Warnings!. Available online: https:\/\/www.eucast.org\/ast_of_bacteria\/warnings\/."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/12\/2473\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:37:50Z","timestamp":1760168270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/9\/12\/2473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["microorganisms9122473"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms9122473","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}